Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan W Partin

Showing results (231-240 of 349) with videos related to

Pageof 35
Sort By:
BJU International|July 2, 2016
Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary eraJeffrey J Tosoian, Meera Chappidi, Zhaoyong Feng, et al.
Urology|October 18, 2002
Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 menLori J Sokoll, Leslie A Mangold, Alan W Partin, et al.
Clinical Prostate Cancer|March 26, 2004
Comparison of total prostate-specific antigen and derivative levels in a screening population of black, white, and Korean-American menJae Park, Lori J Sokoll, Debra J Bruzek, et al.
Reviews in Urology|November 7, 2015
Best of the 2015 AUA Annual Meeting: Highlights From the 2015 American Urological Association Annual Meeting, May 15-19, 2015, New Orleans, LAJ Curtis Nickel, Michael A Gorin, Alan W Partin, et al.
BJU International|February 11, 2020
Utility of multiparametric magnetic resonance imaging in the risk stratification of men with Grade Group 1 prostate cancer on active surveillanceMufaddal K Mamawala, Alexa R Meyer, Patricia K Landis, et al.
Cancer Biology & Therapy|September 6, 2007
Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpointConnie Collins, Michael A Carducci, Mario A Eisenberger, et al.
Urology|March 31, 2010
Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimenPhillip M Pierorazio, Thomas J Guzzo, Misop Han, et al.
The Journal of Urology|December 6, 2016
Implementation of a Surgeon-Level Comparative Quality Performance Review to Improve Positive Surgical Margin Rates during Radical ProstatectomyRichard S Matulewicz, Jeffrey J Tosoian, C J Stimson, et al.
Reviews in Urology|October 16, 2007
Best of the 2007 AUA Annual Meeting: Highlights from the 2007 Annual Meeting of the American Urological Association, May 19-24, 2007, Anaheim, CAMichael K Brawer, Danil V Makarov, Alan W Partin, et al.
The Journal of Urology|February 16, 2005
Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason gradeAlexander Haese, Ville Vaisanen, Hans Lilja, et al.
Pageof 35

Showing results (231-240 of 349) with videos related to

Sort By:
Pageof 35
BJU International|July 2, 2016
Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary eraJeffrey J Tosoian, Meera Chappidi, Zhaoyong Feng, et al.
Urology|October 18, 2002
Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 menLori J Sokoll, Leslie A Mangold, Alan W Partin, et al.
Clinical Prostate Cancer|March 26, 2004
Comparison of total prostate-specific antigen and derivative levels in a screening population of black, white, and Korean-American menJae Park, Lori J Sokoll, Debra J Bruzek, et al.
Reviews in Urology|November 7, 2015
Best of the 2015 AUA Annual Meeting: Highlights From the 2015 American Urological Association Annual Meeting, May 15-19, 2015, New Orleans, LAJ Curtis Nickel, Michael A Gorin, Alan W Partin, et al.
BJU International|February 11, 2020
Utility of multiparametric magnetic resonance imaging in the risk stratification of men with Grade Group 1 prostate cancer on active surveillanceMufaddal K Mamawala, Alexa R Meyer, Patricia K Landis, et al.
Cancer Biology & Therapy|September 6, 2007
Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpointConnie Collins, Michael A Carducci, Mario A Eisenberger, et al.
Urology|March 31, 2010
Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimenPhillip M Pierorazio, Thomas J Guzzo, Misop Han, et al.
The Journal of Urology|December 6, 2016
Implementation of a Surgeon-Level Comparative Quality Performance Review to Improve Positive Surgical Margin Rates during Radical ProstatectomyRichard S Matulewicz, Jeffrey J Tosoian, C J Stimson, et al.
Reviews in Urology|October 16, 2007
Best of the 2007 AUA Annual Meeting: Highlights from the 2007 Annual Meeting of the American Urological Association, May 19-24, 2007, Anaheim, CAMichael K Brawer, Danil V Makarov, Alan W Partin, et al.
The Journal of Urology|February 16, 2005
Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason gradeAlexander Haese, Ville Vaisanen, Hans Lilja, et al.
Pageof 35